Management of HER2-Altered Non-Small Cell Lung Cancer

1

Introduction

00:00 • 5min

2

HER2 Mutant - Is There a Receptor on the Cell Surface?

05:02 • 3min

3

The TDM One Trial in Lung Cancer

08:00 • 3min

4

HER2 Mutation in Non-Small Cell Lung Cancer

10:46 • 2min

5

Amplification in Lung Cancer

12:19 • 5min

6

Is Her-to Mutant Reacting to Immune Checkpoint Inhibitors?

16:59 • 2min

7

PD-1 Levels - Is Her One Really EJFR?

19:00 • 5min

8

HER3 Antibody Drug Conjugate

23:41 • 3min

9

Trastuzumab in Breast Cancer - What's Your Vision?

26:39 • 2min

10

Trastuzumab and Lung Cancer

28:24 • 5min

11

TDM1 and Lung Cancer

33:11 • 3min

12

TDXD - A New Antibody Drug Conjugate Compared to TDM1

36:27 • 5min

13

Drug Development Pathways for ADCs

41:50 • 3min

14

TDXD in Lung Cancer?

45:20 • 3min

15

TDXD and HER2M-Mutin Lung Cancer - What Are the Side Effects?

48:27 • 5min

16

Do You Have a TDXD or Pembrychemo?

53:42 • 4min

17

Cure for Cancer

57:22 • 2min

18

Clinical Trials in Community Practices, You Know?

59:40 • 2min

19

Is It a Randomized Control or an EJFR?

01:01:13 • 2min

20

TDXD First Line Trials - What's the Difference?

01:03:19 • 4min

21

ILD and Lung Cancer - Is That a Good Idea?

01:07:26 • 3min

22

Breast Cancer

01:10:23 • 3min

23

The HER2 Mutation in Lung Cancer Is a Big Thing, but Not So Big in Breast Cancer

01:13:07 • 3min

24

HER2 Low Breast Cancer

01:16:16 • 2min

25

Oncology Today - Dr. Neil Love for Oncology

01:18:01 • 2min